Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Stryker stock

SYK
US8636671013
864952

Price

380.48
Today +/-
+13.44
Today %
+3.75 %

Stryker stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Stryker stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Stryker stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Stryker stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Stryker's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Stryker Stock Price History

DateStryker Price
12/23/2024380.48 undefined
12/23/2024366.49 undefined
12/20/2024364.60 undefined
12/19/2024357.14 undefined
12/18/2024359.17 undefined
12/17/2024370.81 undefined
12/16/2024372.70 undefined
12/13/2024374.60 undefined
12/12/2024375.06 undefined
12/11/2024376.16 undefined
12/10/2024382.68 undefined
12/9/2024381.11 undefined
12/6/2024385.02 undefined
12/5/2024382.45 undefined
12/4/2024389.76 undefined
12/3/2024390.97 undefined
12/2/2024389.63 undefined
11/29/2024392.15 undefined
11/27/2024388.14 undefined
11/26/2024389.71 undefined
11/25/2024384.91 undefined

Stryker Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Stryker, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Stryker from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Stryker’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Stryker. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Stryker’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Stryker’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Stryker’s growth potential.

Stryker Revenue, EBIT and net profit per share

DateStryker RevenueStryker EBITStryker Net Income
2029e32.47 B undefined9.45 B undefined7.66 B undefined
2028e30.37 B undefined8.62 B undefined6.52 B undefined
2027e28.62 B undefined7.9 B undefined6.15 B undefined
2026e26.6 B undefined7.06 B undefined5.74 B undefined
2025e24.67 B undefined6.43 B undefined5.21 B undefined
2024e22.81 B undefined5.72 B undefined4.64 B undefined
202320.5 B undefined4.38 B undefined3.17 B undefined
202218.45 B undefined3.75 B undefined2.36 B undefined
202117.11 B undefined3.5 B undefined1.99 B undefined
202014.35 B undefined2.95 B undefined1.6 B undefined
201914.88 B undefined3.38 B undefined2.08 B undefined
201813.6 B undefined3.09 B undefined3.55 B undefined
201712.44 B undefined2.77 B undefined1.02 B undefined
201611.33 B undefined2.58 B undefined1.65 B undefined
20159.95 B undefined2.26 B undefined1.44 B undefined
20149.68 B undefined2.2 B undefined515 M undefined
20139.02 B undefined2.09 B undefined1.01 B undefined
20128.66 B undefined2.26 B undefined1.3 B undefined
20118.31 B undefined1.76 B undefined1.35 B undefined
20107.32 B undefined1.88 B undefined1.27 B undefined
20096.72 B undefined1.66 B undefined1.11 B undefined
20086.72 B undefined1.55 B undefined1.15 B undefined
20076 B undefined1.33 B undefined1.02 B undefined
20065.15 B undefined1.12 B undefined778 M undefined
20054.61 B undefined948 M undefined644 M undefined
20044.02 B undefined799 M undefined440 M undefined

Stryker Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.080.090.110.130.150.180.230.280.370.480.560.680.870.910.981.12.12.292.63.013.44.024.615.1566.726.727.328.318.669.029.689.9511.3312.4413.614.8814.3517.1118.4520.522.8124.6726.628.6230.3732.47
-20.0020.0019.4414.7320.9526.2624.3429.8930.6816.7722.4427.864.367.6912.5590.758.7913.6715.7612.9518.0814.7411.6716.5911.950.078.8813.484.214.207.252.8013.869.889.309.43-3.5819.217.8411.1111.298.147.827.616.106.93
49.3350.0050.0050.3952.0352.5152.6552.6752.6053.4654.0456.0157.6856.9259.3957.2152.9564.3962.9963.0866.7367.5667.6968.6068.9168.2867.5168.7766.1668.1466.7265.7066.3866.7166.3766.0365.8563.8164.3063.0863.9057.4253.1049.2545.7643.1340.34
0.040.050.050.070.080.090.120.150.190.260.30.380.50.520.580.631.111.471.641.92.272.713.123.534.144.594.545.035.55.96.026.366.67.568.268.989.89.161111.6413.1000000
0.010.010.010.010.010.020.020.030.030.050.060.070.090.10.130.060.020.220.270.350.430.440.640.781.021.151.111.271.351.31.010.521.441.651.023.552.081.61.992.363.174.645.215.746.156.527.66
-16.6728.5711.1130.0023.0818.7578.95-2.9445.4525.0020.0020.8319.5420.19-52.00-68.331,063.1620.8129.5925.431.3846.3620.8130.7212.88-3.5715.005.66-3.49-22.50-48.81179.4214.45-38.07248.33-41.37-23.2424.7018.2534.2246.6712.1710.277.125.9317.59
-----------------------------------------------
-----------------------------------------------
366368369371374380383386390391391392394394393392397402406408406409411412417414399400390383382383381379380380380380382.3382.2383.7000000
-----------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Stryker Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Stryker is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                                 
0.010.010.010.010.040.040.020.050.080.090.150.20.270.370.350.140.080.050.050.040.070.351.061.422.412.22.964.383.424.293.9854.083.382.793.74.433.023.021.933.05
0.010.010.020.030.040.050.050.050.050.080.090.160.160.170.180.430.380.340.330.410.50.750.770.871.031.131.151.251.421.431.521.571.661.972.22.332.892.73.023.573.77
00000000000000000000000000000000000000000
0.010.020.020.0300.010.050.060.080.080.080.120.130.130.120.590.390.390.40.430.470.550.560.680.80.950.941.061.281.271.421.591.642.032.472.962.983.493.3144.84
0000000.010.010.020.020.030.070.060.090.090.180.260.210.210.280.370.490.480.570.670.70.810.941.091.171.420.520.560.480.540.750.760.490.660.790.86
0.030.040.050.070.080.10.130.180.230.270.350.540.620.750.741.341.1110.991.151.42.142.873.534.914.985.857.637.218.158.348.687.947.867.999.7311.069.7110.0210.2812.52
0.010.010.020.020.020.020.020.030.040.060.070.20.180.170.160.430.390.380.440.520.610.71.081.21.291.241.231.090.890.951.081.11.21.571.982.292.953.183.253.443.71
00000000000000000000000000000000000000000
00000000000000000000000000000000000000000
0000000000000.020.050.010.420.380.370.370.480.470.460.410.40.40.370.640.71.441.421.992.021.793.513.484.164.235.554.844.894.59
000000000000000.040.480.520.470.430.460.490.510.510.510.530.570.961.072.072.143.844.194.146.367.178.569.0712.7812.9214.8815.24
0000.010.010.0100.010.010.010.040.030.030.020.040.210.180.220.180.210.190.280.120.220.240.450.40.40.540.540.491.291.151.141.582.482.863.123.63.43.85
0.010.010.020.020.020.030.030.030.040.070.110.230.230.240.251.541.471.431.431.661.761.942.122.342.452.633.223.264.945.067.418.68.2812.5714.217.519.1124.6224.6126.6127.39
0.040.060.070.090.110.130.150.210.270.340.460.770.860.990.982.882.582.432.422.823.164.094.995.877.357.619.0710.912.1513.2115.7417.2816.2220.4422.227.2330.1734.3334.6336.8839.91
                                                                                 
0112222555551010101019202020404041414140403938383838373737373738383838
00000.010.010.010.010.010.020.020.020.020.0100.010.030.060.080.120.150.220.450.570.710.810.90.961.021.11.161.251.321.431.51.561.631.741.892.032.2
0.030.040.040.060.070.080.10.140.170.210.270.340.420.510.610.660.670.871.121.441.872.32.83.494.374.395.46.026.487.337.627.567.798.848.9910.7711.7512.4613.4814.7716.77
0000111220-228-1-9-9-43-102-167-8597196591261165254152144125232-257-639-761-549-627-603-1,154-531-220-416
00000000000-12100000000000042040300-4-4-3-30-10
0.030.040.050.060.080.090.110.150.180.230.290.360.460.530.610.670.670.861.061.52.162.753.34.195.385.416.67.177.688.69.058.68.519.559.9711.7312.8113.0814.8816.6218.59
0.010.010.020.010.010.010.010.020.030.040.040.050.050.060.060.160.110.090.110.110.140.220.210.250.270.270.20.290.350.290.310.330.410.440.490.650.680.811.131.411.52
0000.010.010.010.020.030.040.050.060.080.10.130.140.270.270.30.340.430.550.70.740.770.860.981.031.171.241.42.072.932.032.272.012.422.483.032.963.123.62
1213433691021392657372251859088159139187252320194189194118236172249477292217357370384444455576695
00020332701000000000000000000000000000000
000000.01000000.01000.070.020.110.1400.010.010.010.050.020.020.020.020.030.020.020.030.730.770.230.631.370.860.760.011.192.09
0.010.010.020.020.020.030.040.060.090.10.130.180.180.250.30.670.670.620.530.710.831.111.251.351.331.461.441.611.841.882.664.463.53.153.494.814.45.044.556.37.92
00000000000.030.10.10.0901.491.180.880.720.490.0200.18000011.751.752.743.253.236.696.598.4910.2313.2312.4711.8610.9
0000000000000000000000000000180182397000000068670
0000000000.010.010.040.020.040.030.050.060.080.110.120.150.220.260.330.640.741.041.120.690.810.90.980.981.052.142.212.732.982.732.112.5
00.010.010.010.010.010.01000.010.040.130.120.130.031.531.240.960.830.610.170.220.440.330.640.741.042.122.622.734.044.224.217.748.7310.6912.9616.2115.2714.0313.4
0.010.020.020.030.030.030.040.060.090.110.170.310.30.380.342.21.911.581.371.3211.331.691.681.982.22.483.724.464.616.78.687.7110.8912.2215.517.3621.2519.8220.3421.32
0.040.060.070.090.10.130.150.210.270.340.450.670.750.910.952.882.582.432.432.823.164.094.995.877.367.619.0710.912.1513.2115.7417.2816.2220.4422.1827.2330.1734.3334.736.9539.91
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Stryker provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Stryker's financial health and stability.

Assets

Stryker's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Stryker must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Stryker after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Stryker's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.010.010.020.020.020.030.050.060.070.090.10.130.060.020.220.270.350.450.440.640.781.021.151.111.271.351.31.010.521.441.651.023.552.081.61.992.363.17
00.010.010.010.010.010.010.020.020.030.030.030.050.160.170.170.190.230.250.280.320.370.390.390.220.280.280.310.380.40.550.640.720.780.810.9911.03
0000-1-5-4-2-32-302-33-482829-1-32-727-27-147-17-72-104-164-39236087-4636-1,58212648-23758-206
-7-11-16-71-10-117-3-2135-73-29-171-115-28-64-58-89-185-338-266-463-74-45-323-47396-117-178-333-447-242-1,182396-288-1,225-535
00-000.020.010.010.010.010.020.0600.110.320.030.030.050.060.030.080.130.120.190.180.270.370.240.231.02-0.680.20.420.280.510.560.980.60.46
000000013644121269466372268665500000101180264248286304325324356
681110182225275170628756697563112189235247325411478406579574599321437497510312539457323622505693
0.010.0100.020.050.040.050.090.10.110.20.090.150.280.330.470.520.650.560.830.871.031.181.461.551.431.661.891.780.981.921.562.612.193.283.262.623.71
-5-3-8-7-11-16-31-20-29-36-26-35-51-76-80-161-139-144-187-261-209-187-155-131-182-226-210-195-233-270-490-598-572-649-487-525-588-575
-0.01-0.01-0.01-0.01-0.03-0.03-0.06-0.11-0.05-0.16-0.07-0.08-1.57-0.08-0.09-0.2-0.31-0.15-0.32-0.9-0.74-1.180.31-1.33-0.8-2.14-0.74-2.22-1.881.96-4.19-1.61-2.86-1.46-4.7-0.86-2.92-0.96
-0-000-0.02-0.01-0.03-0.09-0.02-0.13-0.05-0.04-1.52-0-0.01-0.03-0.17-0.01-0.14-0.64-0.53-0.990.47-1.2-0.61-1.91-0.53-2.02-1.652.23-3.7-1.02-2.29-0.81-4.21-0.33-2.34-0.39
00000000000000000000000000000000000000
0-000-00-0.010.030.030-0-0.011.38-0.22-0.25-0.28-0.23-0.48-0.020.22-0.2300.01-01.020.74-01.011.160.052.910.32.461.290.99-1.150.47-0.28
01010191-13-10-2067149192637304869-9496-426-622-108-317-100-700-13-230-300-3070000
0-00000.0100.030.020.01-0.02-0.031.39-0.23-0.26-0.28-0.22-0.480.040.23-0.20.01-1.05-0.190.41-0.16-0.450.30.63-1.222.26-0.791.330-0.01-2.37-0.75-1.59
00000000-11-267-3-6-10052162033321593-131332-50-73-227-124-205-137-262-170-178
000000-2-2-3-3-4-9-10-11-12-15-19-23-28-36-44-89-135-198-238-279-324-401-462-521-568-636-703-778-863-950-1,051-1,139
-0-0-00.010.020.01-0.010.010.07-0.050.11-0.02-0.03-0.04-0.03-0-0.010.030.280.14-0.07-0.130.41-0.041.1-0.850.49-0.060.461.58-0.06-0.771.070.72-1.390-1.11.13
0.52.4-4.614.436.42119.165.968.575.2177.656.7103.2207.6251.1311.3377.2504371.7571.6657.9840.61,020.71,329.41,3651,2081,4471,6911,5497111,4259612,0381,5422,7902,7382,0363,136
00000000000000000000000000000000000000

Stryker stock margins

The Stryker margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Stryker. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Stryker.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Stryker's sales revenue. A higher gross margin percentage indicates that the Stryker retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Stryker's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Stryker's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Stryker's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Stryker. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Stryker's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Stryker Margin History

Stryker Gross marginStryker Profit marginStryker EBIT marginStryker Profit margin
2029e63.9 %29.1 %23.59 %
2028e63.9 %28.37 %21.46 %
2027e63.9 %27.61 %21.49 %
2026e63.9 %26.55 %21.59 %
2025e63.9 %26.07 %21.11 %
2024e63.9 %25.09 %20.35 %
202363.9 %21.35 %15.44 %
202263.08 %20.3 %12.78 %
202164.3 %20.46 %11.66 %
202063.81 %20.54 %11.14 %
201965.85 %22.72 %13.99 %
201866.03 %22.7 %26.12 %
201766.37 %22.24 %8.2 %
201666.71 %22.75 %14.54 %
201566.38 %22.69 %14.47 %
201465.7 %22.72 %5.32 %
201366.72 %23.13 %11.15 %
201268.14 %26.07 %14.99 %
201166.16 %21.21 %16.19 %
201068.77 %25.61 %17.39 %
200967.51 %24.71 %16.47 %
200868.28 %23.13 %17.09 %
200768.91 %22.11 %16.95 %
200668.6 %21.7 %15.12 %
200567.69 %20.57 %13.97 %
200467.56 %19.89 %10.95 %

Stryker Stock Sales Revenue, EBIT, Earnings per Share

The Stryker earnings per share therefore indicates how much revenue Stryker has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Stryker earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Stryker's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Stryker’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Stryker's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Stryker Revenue, EBIT and net profit per share

DateStryker Sales per ShareStryker EBIT per shareStryker Earnings per Share
2029e85.18 undefined0 undefined20.1 undefined
2028e79.67 undefined0 undefined17.09 undefined
2027e75.09 undefined0 undefined16.14 undefined
2026e69.77 undefined0 undefined15.06 undefined
2025e64.71 undefined0 undefined13.66 undefined
2024e59.84 undefined0 undefined12.18 undefined
202353.42 undefined11.4 undefined8.25 undefined
202248.27 undefined9.8 undefined6.17 undefined
202144.75 undefined9.16 undefined5.22 undefined
202037.77 undefined7.76 undefined4.21 undefined
201939.17 undefined8.9 undefined5.48 undefined
201835.79 undefined8.13 undefined9.35 undefined
201732.75 undefined7.28 undefined2.68 undefined
201629.88 undefined6.8 undefined4.35 undefined
201526.1 undefined5.92 undefined3.78 undefined
201425.26 undefined5.74 undefined1.34 undefined
201323.62 undefined5.46 undefined2.63 undefined
201222.6 undefined5.89 undefined3.39 undefined
201121.3 undefined4.52 undefined3.45 undefined
201018.3 undefined4.69 undefined3.18 undefined
200916.85 undefined4.16 undefined2.77 undefined
200816.23 undefined3.75 undefined2.77 undefined
200714.39 undefined3.18 undefined2.44 undefined
200612.49 undefined2.71 undefined1.89 undefined
200511.21 undefined2.31 undefined1.57 undefined
20049.82 undefined1.95 undefined1.08 undefined

Stryker business model

Stryker Corp is a global medical technology company based in Kalamazoo, Michigan, USA. It was founded by Dr. Homer Stryker in 1941 and has since become one of the world's leading providers of medical devices, implants, and medical instruments and accessories. The history of Stryker Corp began over 80 years ago with the invention of the "Gipsbruch", a device developed by Dr. Homer Stryker to better treat broken bones. The Gipsbruch marked the beginning of a new era in orthopedics and led to a comprehensive redefinition of patient care. Over the following decades, Stryker Corp developed further life-saving products and solutions that are used worldwide. Stryker Corp offers a wide range of medical devices, implants, instruments, and accessories to support patient care. The company pursues a strategic growth strategy focused on innovation and acquisitions. This includes the development and marketing of new technologies to enhance patients' quality of life. Stryker Corp is divided into three main divisions: Orthopedics, Medical Technology, and Neurotechnology. The Orthopedics division specializes in the development and manufacturing of implants, instruments, and devices for the treatment of musculoskeletal disorders. The Medical Technology division focuses on the development and manufacturing of devices to support surgical procedures and diagnostics in areas such as endoscopy and emergency medicine. The Neurotechnology division specializes in the development and manufacturing of products for the treatment of neurological disorders such as epilepsy, Parkinson's disease, and hydrocephalus. Some of Stryker Corp's well-known products include the Gipsbruch, which has become a standard device in orthopedics. Other significant products include the hip implant system and the knee implant system, which are widely used and successful in many countries worldwide. Another product of Stryker Corp is the Neptune System, a surgical system that enables the safe and effective use of fluids and gases during surgical procedures. Overall, Stryker Corp is a global medical technology company that originated from the invention of the Gipsbruch and is now one of the leading companies in the manufacturing and development of medical devices and instruments. The company pursues a growth strategy based on innovation and acquisitions and has already produced many successful products. The different divisions, Orthopedics, Medical Technology, and Neurotechnology, each focus on different medical disciplines and offer a wide range of products and solutions to support patient care. Stryker is one of the most popular companies on Eulerpool.com.

Stryker SWOT Analysis

Strengths

1. Strong market presence: Stryker Corp is a leading global medical technology company known for its innovative products and solutions.

2. Diverse product portfolio: The company offers a wide range of medical devices, orthopedic implants, surgical equipment, and other healthcare products, enabling it to cater to various healthcare needs.

3. Established brand reputation: Stryker Corp has built a strong brand image over the years, known for its quality, reliability, and advanced technology.

4. Strong financial performance: The company has consistently delivered positive financial results, with significant revenue growth and profitability.

Weaknesses

1. Dependence on key markets: Stryker Corp relies heavily on specific geographic regions for its revenue, making it vulnerable to fluctuations in those markets.

2. Vulnerability to regulations: The medical technology industry is subject to stringent regulations and compliance requirements, which may pose challenges for the company's operations.

3. Limited manufacturing capacity: In some product categories, Stryker Corp may face constraints in scaling up production to meet growing demand.

Opportunities

1. Growing global healthcare market: The increasing healthcare needs, particularly in emerging markets, present opportunities for Stryker Corp to expand its customer base and introduce new products.

2. Technological advancements: Stryker Corp can leverage advancements in areas such as robotics, digital health, and artificial intelligence to develop innovative and differentiated products.

3. Expansion through acquisitions: The company can explore strategic acquisitions to enhance its product offerings, enter new markets, or strengthen its existing market presence.

Threats

1. Intense competition: Stryker Corp operates in a highly competitive market, facing competition from both established medical technology companies and new entrants.

2. Economic instability: Fluctuations in global economic conditions can impact healthcare spending, thereby affecting the demand for Stryker Corp's products.

3. Product recalls or liabilities: Any product recalls or legal liabilities related to the company's products could damage its reputation and result in financial losses.

Stryker Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Stryker Revenue by Segment

Segmente2023202220212020201920182017201620152014201220112010
Other MedSurg And Neurotechnology343 M USD------------

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Stryker Revenue by Segment

Segmente2023202220212020201920182017201620152014201220112010
Trauma and Extremities850 M USD772 M USD798 M USD583 M USD588 M USD1.58 B USD-------
Medical674 M USD609 M USD600 M USD614 M USD477 M USD2.12 B USD-------
Knees597 M USD504 M USD497 M USD397 M USD469 M USD1.7 B USD-------
Endoscopy555 M USD509 M USD471 M USD355 M USD406 M USD1.85 B USD-------
Instruments518 M USD469 M USD474 M USD392 M USD433 M USD1.82 B USD-------
Hips556 M USD517 M USD520 M USD429 M USD500 M USD1.34 B USD-------
Neurotechnology---763 M USD702 M USD1.74 B USD-------
Spine306 M USD310 M USD336 M USD283 M USD268 M USD828 M USD-------
Neurovascular743 M USD754 M USD737 M USD----------
Other163 M USD121 M USD124 M USD77 M USD81 M USD374 M USD-------
Neuro Cranial279 M USD241 M USD226 M USD----------
Sustainability---3 M USD3 M USD259 M USD-------

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Stryker Revenue by Segment

Segmente2023202220212020201920182017201620152014201220112010
MedSurg and Neurotechnology11.84 B USD10.61 B USD9.54 B USD----------
MedSurg---6.4 B USD--5.56 B USD4.89 B USD3.9 B USD3.78 B USD3.27 B USD3.16 B USD-
Orthopaedics---4.96 B USD5.25 B USD4.99 B USD4.71 B USD4.42 B USD-----
Orthopaedics and Spine8.66 B USD7.84 B USD7.57 B USD----------
United States----------5.66 B USD5.27 B USD4.79 B USD
Ortho--------4.22 B USD4.15 B USD---
Neuro and Spine------2.17 B USD2.01 B USD1.83 B USD1.74 B USD---
Reconstructive----------3.82 B USD3.71 B USD-
Neurotechnology and Spine---2.99 B USD------1.57 B USD--
Orthopaedic Implants------------4.31 B USD
MedSurg Equipment------------3.01 B USD
Other foreign countries----------397 M USD1.66 B USD-
Neurotechnology And Spine-----------1.44 B USD-
Asia Pacific----------1.34 B USD--
Other European countries-----------1.32 B USD-
Other Foreign Countries------------1.3 B USD
Europe, Middle East, Africa----------1.27 B USD--
Europe Middle East Africa------------1.23 B USD
Ireland-----------63 M USD-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Stryker Revenue by Segment

Segmente2023202220212020201920182017201620152014201220112010
MedSurg----6.57 B USD6.05 B USD-------
Neuro and Spine----3.06 B USD--------
Neurotechnology and Spine-----2.57 B USD-------

Stryker Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Stryker Revenue by Segment

DateAsia PacificEurope, Middle East, AfricaEurope, Middle East, and AfricaInternationalOther foreign countriesUnited States
20231.95 B USD2.62 B USD-5.24 B USD677 M USD15.26 B USD
20221.89 B USD2.35 B USD-4.81 B USD578 M USD13.64 B USD
20211.97 B USD2.3 B USD-4.79 B USD515 M USD12.32 B USD
20201.63 B USD1.82 B USD-3.9 B USD448 M USD10.46 B USD
20191.62 B USD1.89 B USD-3.93 B USD422 M USD10.96 B USD
20181.53 B USD1.79 B USD-1.61 B USD428 M USD3.38 B USD
20171.41 B USD1.57 B USD--405 M USD9.06 B USD
20161.31 B USD1.44 B USD--322 M USD8.25 B USD
20151.25 B USD-1.27 B USD-312 M USD7.12 B USD
20141.37 B USD-1.37 B USD-378 M USD6.56 B USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Stryker Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Stryker historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Stryker shares outstanding

The number of shares was Stryker in 2023 — This indicates how many shares 383.7 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Stryker earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Stryker's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Stryker’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Stryker's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Stryker stock splits

In Stryker's history, there have been no stock splits.

Stryker dividend history and estimates

In 2023, Stryker paid a dividend amounting to 3.05 USD. Dividend means that Stryker distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Stryker provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Stryker’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Stryker's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Stryker Dividend History

DateStryker Dividend
2029e3.27 undefined
2028e3.27 undefined
2027e3.27 undefined
2026e3.27 undefined
2025e3.27 undefined
2024e3.27 undefined
20233.05 undefined
20222.84 undefined
20212.59 undefined
20202.36 undefined
20192.14 undefined
20181.93 undefined
20171.74 undefined
20161.57 undefined
20151.42 undefined
20141.87 undefined
20131.63 undefined
20120.9 undefined
20110.75 undefined
20100.63 undefined
20090.25 undefined
20080.4 undefined
20070.33 undefined
20060.22 undefined
20050.11 undefined
20040.09 undefined

Stryker dividend payout ratio

In 2023, Stryker had a payout ratio of 50.53%. The payout ratio indicates the percentage of the company's profits that Stryker distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Stryker represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Stryker could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Stryker's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Stryker Payout Ratio History

DateStryker Payout ratio
2029e48.91 %
2028e48.78 %
2027e48.75 %
2026e49.2 %
2025e48.39 %
2024e48.68 %
202350.53 %
202245.95 %
202149.56 %
202056.07 %
201938.96 %
201820.64 %
201765.11 %
201635.98 %
201537.43 %
2014138.52 %
201361.98 %
201226.62 %
201121.81 %
201019.75 %
20099.03 %
200814.39 %
200713.58 %
200611.76 %
20057.05 %
20048.41 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Stryker.

Stryker latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20242.8 2.87  (2.52 %)2024 Q3
6/30/20242.82 2.81  (-0.26 %)2024 Q2
3/31/20242.38 2.5  (5.12 %)2024 Q1
12/31/20233.3 3.46  (4.82 %)2023 Q4
9/30/20232.46 2.46  (0.04 %)2023 Q3
6/30/20232.4 2.54  (5.8 %)2023 Q2
3/31/20232.02 2.14  (5.79 %)2023 Q1
12/31/20222.87 3  (4.69 %)2022 Q4
9/30/20222.25 2.12  (-5.87 %)2022 Q3
6/30/20222.3 2.25  (-2.16 %)2022 Q2
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Stryker stock

Eulerpool World ESG Rating (EESG©)

74/ 100

🌱 Environment

58

👫 Social

79

🏛️ Governance

86

Environment

Scope 1 - Direct Emissions
57,383
Scope 2 - Indirect emissions from purchased energy
117,059
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
174,442
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees37.5
Percentage of women in management
Percentage of Asian employees7.7
Share of Asian management11.3
Percentage of Hispanic/Latino employees10.7
Hispano/Latino Management share5.4
Percentage of Black employees6.2
Black Management Share2.6
Percentage of white employees69.1
White Management Share75.4
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Stryker shareholders

%
Name
Stocks
Change
Date
8.37155 % The Vanguard Group, Inc.31,914,013600,4246/30/2024
5.26107 % Brown (John W)20,056,24502/29/2024
4.85946 % Greenleaf Trust18,525,225-28,2219/30/2024
4.49027 % BlackRock Institutional Trust Company, N.A.17,117,804-83,6726/30/2024
3.74234 % State Street Global Advisors (US)14,266,555-86,0666/30/2024
2.94728 % Wellington Management Company, LLP11,235,636399,2346/30/2024
2.94081 % T. Rowe Price Associates, Inc.11,210,966-197,6126/30/2024
1.92311 % Capital Research Global Investors7,331,275-2,651,4426/30/2024
1.79158 % JP Morgan Asset Management6,829,8572,257,9196/30/2024
1.76791 % Geode Capital Management, L.L.C.6,739,636158,6246/30/2024
1
2
3
4
5
...
10

Stryker Executives and Management Board

Mr. Kevin Lobo

(58)
Stryker Chairman of the Board, President, Chief Executive Officer (since 2011)
Compensation 18.56 M

Mr. Glenn Boehnlein

(61)
Stryker Chief Financial Officer, Vice President
Compensation 5.85 M

Mr. J. Andrew Pierce

(49)
Stryker Group President - MedSurg and Neurotechnology
Compensation 5.74 M

Mr. Spencer Stiles

(46)
Stryker Group President - Orthopaedics and Spine
Compensation 5.71 M

Mr. Viju Menon

(55)
Stryker Group President - Global Quality and Operations
Compensation 3.68 M
1
2
3
4

Stryker Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Apria, Inc. Stock
Apria, Inc.
SupplierCustomer -0,620,07-0,17-0,05
Georg Fischer Stock
Georg Fischer
SupplierCustomer0,800,790,210,120,390,86
Materialise ADR Stock
Materialise ADR
SupplierCustomer0,730,810,420,230,19-0,26
Mentice Stock
Mentice
SupplierCustomer0,710,430,240,130,540,43
medmix Stock
medmix
SupplierCustomer0,670,860,150,08
Yantai Zhenghai Bio-Tech A Stock
Yantai Zhenghai Bio-Tech A
SupplierCustomer0,650,860,220,01-0,38-0,36
Kaman A Stock
Kaman A
SupplierCustomer0,650,770,660,69-0,21-0,02
Datronix Stock
Datronix
SupplierCustomer0,620,02-0,29-0,31 0,16
CHC Healthcare Group Stock
CHC Healthcare Group
SupplierCustomer0,620,610,220,18-0,16-0,40
China Chemical & Pharmaceutical Co., Ltd. Stock
China Chemical & Pharmaceutical Co., Ltd.
SupplierCustomer0,60-0,33-0,26-0,15-0,10-0,12
1
2

Most common questions regarding Stryker

What values and corporate philosophy does Stryker represent?

Stryker Corp represents values of innovation, integrity, and excellence in the medical technology industry. The company's corporate philosophy centers around delivering high-quality products and services that improve patient outcomes and enhance healthcare providers' capabilities. By continually investing in research and development, Stryker strives to introduce cutting-edge solutions that address critical healthcare needs and promote sustainable growth. With a commitment to ethical business practices and global collaboration, Stryker focuses on delivering value to its stakeholders, including healthcare professionals, patients, employees, and shareholders. Stryker Corp's dedication to advancing medical technology and improving lives embodies its core values and corporate philosophy.

In which countries and regions is Stryker primarily present?

Stryker Corp is primarily present in various countries and regions worldwide. Some of the key locations include the United States, where the company is headquartered in Kalamazoo, Michigan. Additionally, Stryker has a significant presence in Europe, with operations in countries such as Germany, France, the United Kingdom, Italy, and Switzerland. The company is also active in the Asia-Pacific region, specifically in countries like China, Japan, India, and Australia. With its global reach, Stryker Corp ensures its innovative medical technologies and products are available to healthcare professionals and patients across different parts of the world.

What significant milestones has the company Stryker achieved?

Stryker Corp has achieved significant milestones throughout its history. A major accomplishment for the company was the development and introduction of the first-ever surgical navigation system, the Navigation System II. This technology revolutionized surgical procedures by providing real-time imaging and guidance to surgeons, improving precision and patient outcomes. Another notable milestone for Stryker Corp was the acquisition of Howmedica, a leading orthopedic company, in 1998. This strategic move further strengthened Stryker Corp's position in the medical technology industry, enhancing its product portfolio and global presence. Over the years, the company has continued to innovate and has been recognized for its advancements in medical devices and solutions.

What is the history and background of the company Stryker?

Stryker Corp is a renowned American medical technology company established in 1941. With over 80 years of experience, Stryker has evolved into a global leader specializing in surgical equipment and orthopedic implants. The company's roots trace back to its founding by Dr. Homer Stryker, an innovative orthopedic surgeon who developed various medical devices. Today, Stryker Corp offers a wide range of products across multiple medical disciplines, including reconstructive devices, neurotechnology, spine systems, and more. The company's commitment to innovation, coupled with strategic acquisitions, has solidified its position as a trusted name in the medical industry.

Who are the main competitors of Stryker in the market?

The main competitors of Stryker Corp in the market are Johnson & Johnson, Medtronic, Zimmer Biomet Holdings, and Boston Scientific.

In which industries is Stryker primarily active?

Stryker Corp is primarily active in the healthcare industry.

What is the business model of Stryker?

The business model of Stryker Corp focuses on providing innovative medical technologies and solutions worldwide. As a leading medical technology company, Stryker Corp specializes in products and services across various segments, including orthopedics, medical and surgical, neurotechnology, and spine. With a strong emphasis on research and development, Stryker Corp strives to deliver advanced and effective healthcare solutions to improve patient outcomes. The company's commitment to innovation, quality, and customer satisfaction has made it a trusted name in the medical industry. Stryker Corp's business model revolves around leveraging its expertise and cutting-edge technologies to meet the evolving needs of healthcare professionals and enhance the lives of patients.

What is the P/E ratio of Stryker 2024?

The Stryker P/E ratio is 31.45.

What is the P/S ratio of Stryker 2024?

The Stryker P/S ratio is 6.4.

What is the Quality Investing of Stryker?

The Quality Investing for Stryker is 9/10.

What is the revenue of Stryker 2024?

The expected Stryker revenue is 22.81 B USD.

How high is the profit of Stryker 2024?

The expected Stryker profit is 4.64 B USD.

What is the business model of Stryker

Stryker Corp is a US-American company that specializes in the manufacturing and sale of medical devices, implantable products, and medical services. The company was founded in 1941 and has since become a leading company in the medical technology industry. Stryker has four business segments, namely Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. In the Medical Devices segment, Stryker offers a wide range of products including endoscopy devices, respiratory devices, patient monitoring devices, neurological monitoring devices, and medical lighting systems. These products are used in hospitals and clinical facilities for patient diagnosis and treatment. In Orthopedics, Stryker is one of the world leaders in implants and instruments for joint surgery. The company offers products for the hip, knee, shoulder, wrist, and other joints. Stryker has also taken a leading role in introducing robotics in surgery in this field. The Mako robot allows for precise implantations, enabling patients to have faster recovery and improved quality of life. The Medical and Surgical Instruments segment includes a wide range of instruments for surgery, including surgical saws, scalpels, forceps, and other instruments for various surgical procedures. These instruments are used by physicians for a variety of surgical interventions. In the Neurotechnology and Spine Products segment, Stryker develops and distributes products for spinal surgery, including implants for intervertebral discs and for stabilization of the cervical and lumbar spine. In addition to selling products, Stryker also offers medical services. This includes consulting and support for the implementation of products and systems in hospitals and medical facilities. Technical support and customer service are also part of the offerings. Stryker's business model is based on its ability to develop and produce innovative and high-quality products for the medical field. The company emphasizes close collaboration with medical professionals to ensure that the offered products meet the requirements of the practice and enable optimal treatment for patients. The company also strives to continuously improve its products and develop new technologies. In particular, the introduction of robotics in surgery offers Stryker significant growth opportunities as it has the potential for higher efficiency, precision, and better treatment outcomes. Overall, Stryker is a leading company in the medical technology industry, specializing in the development of innovative products and the provision of high-quality medical services. The company has a wide range of products in various business segments, including Medical Devices, Orthopedics, Medical and Surgical Instruments, and Neurotechnology and Spine Products. Stryker's business model is based on serving medical professionals with high-quality products and services and developing innovative technologies to achieve even better treatment outcomes for patients.

What is the Stryker dividend?

Stryker pays a dividend of 2.84 USD distributed over 4 payouts per year.

How often does Stryker pay dividends?

Stryker pays out a dividend 4 times a year.

What is the Stryker ISIN?

The ISIN of Stryker is US8636671013.

What is the Stryker WKN?

The WKN of Stryker is 864952.

What is the Stryker ticker?

The ticker of Stryker is SYK.

How much dividend does Stryker pay?

Over the past 12 months, Stryker paid a dividend of 3.05 USD . This corresponds to a dividend yield of about 0.8 %. For the coming 12 months, Stryker is expected to pay a dividend of 3.27 USD.

What is the dividend yield of Stryker?

The current dividend yield of Stryker is 0.8 %.

When does Stryker pay dividends?

Stryker pays a quarterly dividend. This is distributed in the months of April, July, October, January.

How secure is the dividend of Stryker?

Stryker paid dividends every year for the past 34 years.

What is the dividend of Stryker?

For the upcoming 12 months, dividends amounting to 3.27 USD are expected. This corresponds to a dividend yield of 0.89 %.

In which sector is Stryker located?

Stryker is assigned to the 'Health' sector.

Wann musste ich die Aktien von Stryker kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Stryker from 1/31/2025 amounting to 0.84 USD, you needed to have the stock in your portfolio before the ex-date on 12/31/2024.

When did Stryker pay the last dividend?

The last dividend was paid out on 1/31/2025.

What was the dividend of Stryker in the year 2023?

In the year 2023, Stryker distributed 2.835 USD as dividends.

In which currency does Stryker pay out the dividend?

The dividends of Stryker are distributed in USD.

All fundamentals about Stryker

Our stock analysis for Stryker Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stryker Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.